In a new job - January 11, 2021
Alligator Bioscience recruits new Chief Medical Officer
Alligator Bioscience has appointed Dr Christina Reimer as Chief Medical Officer. Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. She will report to Head of R&D, EVP Malin Carlsson, and be part of […]
Biotech Business - December 10, 2020
Alligator Bioscience announces an approved IND
Alligator Bioscience has announced an approved IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND approval by the US Food and Drug Administration (FDA) is a prerequisite to start clinical trials in the USA. Recently, new benchmark data was published showing that mitazalimab has the potential to be best-in-class in the CD40 field, […]
In a new job - October 14, 2020
Alligator Bioscience appoints Chief Business Officer
Alligator Bioscience has appointed Gayle Mills as Chief Business Officer to lead the company’s Business Development activities. Mills will be a member of the executive management team at Alligator Bioscience. Executing large R&D collaborations and transactions Gayle Mills is a renowned business development professional with an unmatched industry network and an extensive knowledge of the […]
Clinical Trials - April 27, 2020
Promising data from Alligator Bioscience
Alligator Bioscience has presented the status of its ongoing Phase I clinical trial with the bispecific drug candidate ATOR-1015 developed as tumor-directed therapy for metastatic cancer. This far, doses of 400 mg (about 6 mg/kg) have been evaluated in the ongoing study and the current dosing is 600 mg (about 10 mg/kg). 18 patients with […]
Clinical Trials - December 19, 2019
First patient dosed with Alligator’s ATOR-1017 developed for metastasized cancer
The first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer. The Phase I study is a dose escalation study in patients with advanced cancer and this is the first time ATOR-1017 is being evaluated in humans. […]
In a new job - December 11, 2019
Per-Olof Schrewelius leaves Alligator Bioscience
Alligator Bioscience has announced that CFO (Chief Financial Officer) Per-Olof Schrewelius leaves the company to become CFO of Nordic Waterproofing. Per-Olof Schrewelius was recruited to Alligator in connection with the IPO in the fall of 2016 and has been responsible for building up the finance function in accordance with Nasdaq Stockholm’s regulations. “We have almost […]
